These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37660283)

  • 1. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.
    Barrera-Baena P; Rodríguez-García M; Rodríguez-Rubio E; González-Llorente L; Ortiz A; Zoccali C; Locatelli F; Floege J; Cohen-Solal M; Ferreira MA; Ketteler M; London GM; Gorriz-Teruel JL; Sánchez-Álvarez E; Hevia-Suárez MÁ; Fernández-Gómez JM; Martín-Carro B; Gómez-Alonso C; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL;
    Nephrol Dial Transplant; 2024 Mar; 39(4):618-626. PubMed ID: 37660283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
    Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB;
    Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COSMOS: the dialysis scenario of CKD-MBD in Europe.
    Fernández-Martín JL; Carrero JJ; Benedik M; Bos WJ; Covic A; Ferreira A; Floege J; Goldsmith D; Gorriz JL; Ketteler M; Kramar R; Locatelli F; London G; Martin PY; Memmos D; Nagy J; Naves-Díaz M; Pavlovic D; Rodríguez-García M; Rutkowski B; Teplan V; Tielemans C; Verbeelen D; Wüthrich RP; Martínez-Camblor P; Cabezas-Rodriguez I; Sánchez-Alvarez JE; Cannata-Andia JB
    Nephrol Dial Transplant; 2013 Jul; 28(7):1922-35. PubMed ID: 23166310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis.
    Martín-Carro B; Navarro-González JF; Ortiz A; Zoccali C; Floege J; Ferreira MA; Gorriz-Teruel JL; Carrillo-López N; Panizo S; Locatelli F; Ketteler M; London GM; Naves-Díaz M; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL
    Nephrol Dial Transplant; 2023 Oct; 38(11):2589-2597. PubMed ID: 37349949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study.
    Yun HJ; Ryoo SR; Kim JE; Choi YJ; Park I; Shin GT; Kim H; Jeong JC
    BMC Nephrol; 2020 Jul; 21(1):299. PubMed ID: 32711466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.
    Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H
    Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.
    Melamed ML; Eustace JA; Plantinga L; Jaar BG; Fink NE; Coresh J; Klag MJ; Powe NR
    Kidney Int; 2006 Jul; 70(2):351-7. PubMed ID: 16738536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study.
    Jørgensen HS; Winther S; Bøttcher M; Hauge EM; Rejnmark L; Svensson M; Ivarsen P
    BMC Nephrol; 2017 Sep; 18(1):284. PubMed ID: 28874132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
    Floege J; Kim J; Ireland E; Chazot C; Drueke T; de Francisco A; Kronenberg F; Marcelli D; Passlick-Deetjen J; Schernthaner G; Fouqueray B; Wheeler DC;
    Nephrol Dial Transplant; 2011 Jun; 26(6):1948-55. PubMed ID: 20466670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures.
    Xie L; Hu X; Li W; Ouyang Z
    BMC Nephrol; 2021 Jan; 22(1):23. PubMed ID: 33430788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic fracture risk in the renal replacement therapy population.
    Dey V; Farrah TE; Traynor JP; Spalding EM; Robertson SE; Geddes CC
    Nephrol Dial Transplant; 2017 Jul; 32(7):1211-1216. PubMed ID: 27257273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Phosphate Is Associated With Fracture Risk: The Rotterdam Study and MrOS.
    Campos-Obando N; Koek WNH; Hooker ER; van der Eerden BC; Pols HA; Hofman A; van Leeuwen JP; Uitterlinden AG; Nielson CM; Zillikens MC
    J Bone Miner Res; 2017 Jun; 32(6):1182-1193. PubMed ID: 28177140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
    Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
    Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.